Développement et utilisation de systèmes d'amplification transcriptionnelle multigéniques à des fins diagnostiques et thérapeutiques pour améliorer la prise en charge du cancer de la prostate

 

Frédéric Pouliot

Centre de recherche du CHU de Québec-Université Laval

 

Domaine :  cancer

Programme chercheurs-boursiers-cliniciens  - Junior 2

Concours 2017-2018

Prostate cancer (PCa) can be treated by surgery (radical prostatectomy, RP) or radiation therapy when it is only located in the pelvis. After RP, Prostate Specific Antigen (PSA) measured in patient's blood should be undetectable. If PSA rise, it means there is PCa recurrence and further treatments are considered. Patients can undergo so-called pelvic salvage RT if the cancer is located only in the pelvis, or hormonal therapy (HT) when the cancer has spread to other organs. HT aims to remove male hormones also called androgens (castration). From this point, PCa is incurable and PCa will become eventually resistant to castration. Castration resistant PCa (CRPC) can be treated to prolong patient's life.

Nowadays, five treatments have been shown to prolong patient's life. Unfortunately, clinical tools to predict which treatment each patient should receive are inaccurate which means that many patients will progress under a treatment while another treatment would have stopped cancer growth. Our research program aims to develop and exploit techniques we have developed to amplify PCa cell molecular alterations for therapeutic and diagnostic purposes. Our specific aims are to: 1) Better personalize CRPC treatments by assessing patient's PCa cell sensitivity to CRPC drugs; 2) Improve localized and recurrent PCa treatment by developing an immunotherapy targeting genetic alterations found in PCa.